In short: Belski's favourite of the big three legacy pharma names, and on Goldman's best-positioned-into-year-end basket. "J&J's done an amazing job post the whole vaccine issue in terms of really thinking about diversifying out their product line. Of those big three, J&J by far is our favorite." His summary ranking: "in terms of where the fundamental growth is, it's J&J and Merck."
Johnson & Johnson is the name Belski picks first out of the three legacy pharmaceutical giants. His reason is diversification: after the reputational and business problems around vaccines, the company deliberately widened its product range instead of defending the old one, so no single franchise carries the company.
Goldman Sachs has it in a basket of healthcare names it thinks are best placed into the end of the year, which is corroboration rather than the argument. Belski's own summary is the useful line: of the big three, growth is at Johnson & Johnson and Merck, and Pfizer is something else — a cheap stock hoping for a turnaround.
In short: The healthcare name he pulls out of the topping bucket: "it looks to me like semis, healthcare and financials are topping right now… Healthcare, Johnson and Johnson." Farley's framing supports the timing read — healthcare "had been a laggard but has been recently catching a bid," and the recent bid is one of the flows filling the hole the semiconductor sell-off left.
Johnson & Johnson is the large pharmaceutical and medical-device company, and it stands here for healthcare as a whole.
Healthcare is the second of his three topping sectors, and Johnson & Johnson is the name he pulls out of it. Farley's framing explains why the timing matters: healthcare "had been a laggard but has been recently catching a bid" — that is, it has just finished a period of outperformance after a long stretch of underperformance.
That is precisely the shape Dillian distrusts. A defensive sector that suddenly starts working while the market's leadership is being sold is usually absorbing rotation money, and rotation destinations are where his chart sweep keeps finding tops rather than beginnings.
8:49On the Macro Dirt podcast that I do with Tony Greer, I talked about financials topping a couple weeks ago. I talked about how JP Morgan was a pretty good short. Goldman Sachs, Morgan Stanley, Wells Fargo all look like they're topping. Healthcare, Johnson and Johnson, and also Nvidia, AMD, couple of other semi names — I'm seeing some charts that are bottoming interestingly enough.
In short: A named survivor — seventh at $178.80bn in 2005, eighteenth at $575.37bn in 2026. Also #13 on the Lindy list a week earlier, where it was argued positively; here it appears only as survivorship evidence.
In short: #13. Founded 1886, IPO 1944 — the best absolute record in Part I. "People will always need healthcare. It sells products that hospitals and patients depend on. Its size allows it to keep developing new medicines and products." Total return 8,000% since 1990. Began as a maker of sterile surgical dressings. One of only six companies in the S&P 500's top twenty in both 2005 and 2026, a fact used in the 13 August issue.
Johnson & Johnson sells prescription medicines and the devices hospitals use — implants, surgical tools, diagnostics. It started in 1886 making sterile surgical dressings, at a time when the idea that bandages ought to be sterile was itself new.
The durability argument is the least contestable on the list: illness is permanent, hospitals depend on these products daily, and the company is large enough to keep funding the research that replaces expiring patents. That last point is the real mechanism — a drug company's individual products all die, so what survives is the machine that produces new ones. Total return of 8,000% since 1990, the best in this half of the list, and one of only six companies in the S&P 500's twenty largest in both 2005 and 2026.
In short: Passing mention in the Hugo bear case — J&J "is also competing aggressively" in surgical robotics alongside Intuitive.
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.